Status:
TERMINATED
A Safety and Efficacy Study of MSI-1256F (Squalamine Lactate) To Treat "Wet" Age-Related Macular Degeneration
Lead Sponsor:
Genaera Corporation
Conditions:
Macular Degeneration
Eligibility:
All Genders
50+ years
Phase:
PHASE2
Brief Summary
Age-Related Macular Degeneration (AMD) is a degenerative eye disease of the retina that causes a progressive loss of central vision. AMD is the leading cause of legal blindness among adults age 50 or ...
Eligibility Criteria
Inclusion
- Patients with a diagnosis of "wet" age-related macular degeneration
Exclusion
- Prior treatment of "wet" age-related macular degeneration in the affected eye in the past 3 months
Key Trial Info
Start Date :
August 1 2004
Trial Type :
INTERVENTIONAL
End Date :
May 1 2007
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT00089830
Start Date
August 1 2004
End Date
May 1 2007
Last Update
November 28 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Genaera Corporation
Plymouth Meeting, Pennsylvania, United States, 19462